CSET's Steph Batalis shared her expert analysis in an op-ed published by DefenseOne. In her piece, she highlights how the United States’ faltering response to the ongoing measles outbreak reveals serious vulnerabilities in the nation’s public health and biodefense infrastructure.

Jack Corrigan and Vikram Venkatram shared their expert analysis in an op-ed published by The National Interest. In their piece, they examine the political and legal controversy surrounding the Biden administration’s draft guidance on “march-in rights” under the Bayh-Dole Act, which could allow federal agencies to lower drug prices by reclaiming patents on taxpayer-funded inventions when they are not reasonably accessible to the public.

Opposing narratives around AI for biotechnology raise the question: how are biotech researchers actually using AI in published research? CSET’s Steph Batalis, Catherine Aiken, and James Dunham explored this question by leveraging CSET’s merged academic corpus, enriched publication metadata, and research clusters.

CSET's Steph Batalis and Vikram Venkatram shared their expert analysis in an op-ed published by The Bulletin of the Atomic Scientists. The article explores discusses the complexities and challenges of screening DNA synthesis orders to prevent misuse of potentially dangerous genetic sequences.

In response to the Office of Science and Technology Policy's request for input on an AI Action Plan, CSET provides key recommendations for advancing AI research, ensuring U.S. competitiveness, and maximizing benefits while mitigating risks. Our response highlights policies to strengthen the AI workforce, secure technology from illicit transfers, and foster an open and competitive AI ecosystem.

Dr. Steph Batalis and Vikram Venkatram offered the following comment in response to the National Institute of Standards and Technology's request for information on safety considerations for chemical and biological AI models.

Artificial intelligence (AI) tools pose exciting possibilities to advance scientific, biomedical, and public health research. At the same time, these tools have raised concerns about their potential to contribute to biological threats, like those from pathogens and toxins. This report describes pathways that result in biological harm, with or without AI, and a range of governance tools and mitigation measures to address them.

Artificial intelligence is becoming more integrated into the sciences. One of the scientific fields experiencing this is computational biology, which uses computer modeling to understand biological mechanisms and systems. This blog post provides an understanding of important research trends in these subject areas, and how advancements in AI can improve the speed and efficiency of computational biology to improve human health and well-being.

Now that the first set of milestones has passed for the Biden administration’s October 2023 executive order on artificial intelligence, where do things stand for biotech? This blog post gives an overview of the most recent action items, with a recap of expert commentary from CSET’s June 2024 Webinar on the AIxBio Policy Landscape.

On June 6, CSET hosted experts to discuss where AIxBio policymakers go next after the 180-day mark following the Biden AI Executive Order.